Letrozole acts as a non-steroidal aromatase inhibitor for hormone-sensitive applications. Peripheral conversion of androgens to estrogens is blocked to reduce hormonal support for specific cell types and manage tissue growth.
Targeting estrogen synthesis, Letrozole belongs to the aromatase inhibitor class and reduces circulating estrogen levels. This low-molecular-weight compound is synthesized chemically and functions primarily to slow the growth of hormone-sensitive tissues. The active ingredient appears in products such as Femara, which are widely available in Singaporean pharmacies. Patients often encounter it when managing conditions linked to excess estrogen production.
Formulated as oral tablets, Letrozole appears in products such as Femara sold across Singapore. The medication is offered in 2.5 mg film-coated tablets, with generic versions meeting the same regulatory standards set by the Health Sciences Authority. Both branded and generic tablets share identical dosage strengths, allowing pharmacists to dispense interchangeable options while maintaining consistent therapeutic intent.
Addressing hormone-driven conditions, this agent is employed for several clinical indications. Post-menopausal individuals with estrogen receptor-positive breast cancer often receive it to help limit tumor progression. Women undergoing ovulation induction may be prescribed it off-label to lower estrogen feedback and promote follicular growth. In rare cases, clinicians consider it for certain gynecologic disorders where estrogen reduction improves symptoms. Overall, the medication targets patients whose disease biology is linked to excess estrogen activity.
Lowering estrogen production, the compound interferes with a key enzyme that converts androgens to estrogen. By blocking this step, overall estrogen levels fall, which can slow the proliferation of cells that rely on the hormone for growth. The effect unfolds gradually, allowing clinicians to monitor changes in disease markers over time while patients experience a steady reduction in estrogen-driven activity.
Experiencing mild, transient effects, many patients report hot flashes, fatigue, or joint discomfort during the initial weeks of therapy. These sensations usually resolve without medical intervention.
Developing severe symptoms such as liver inflammation, pronounced skin rash, or unexpected swelling demands immediate medical attention, as they may indicate rare but serious toxicity.
Excluding individuals who are pregnant, have known hypersensitivity to aromatase inhibitors, or suffer from severe hepatic impairment prevents exposure to unnecessary risk.
Avoiding concurrent use of hormone replacement therapy and strong CYP enzyme inhibitors reduces the chance of altered drug levels. Users should reference the specific medication’s insert for a comprehensive interaction list.
Storing tablets in a dry, room-temperature environment maintains stability throughout the prescribed course. Treatment duration varies; some regimens extend for several years in chronic disease management, while others last only a few months for short-term hormonal modulation. Formulation differences between Femara tablets do not affect the core active compound. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This educational overview of Letrozole is not medical advice; individual medicines such as Femara differ in strength, formulation, and instructions. The provider disclaims liability for any clinical application of the information presented. Patients should review the specific medication labeling and seek guidance from a licensed healthcare professional before making any health-related decisions.
